Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells

Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells

Abstract Immune checkpoint inhibitor (ICI) clinically benefits cancer treatment. However, the ICI responses are only achieved in a subset of patients, and the underlying mechanisms of the limited response remain unclear. 160 patients with non‐small cell lung cancer treated with anti‐programmed cell...

Full description

Bibliographic Details
Main Authors: Se‐Hoon Lee, Yeongmin Kim, Bu‐Nam Jeon, Gihyeon Kim, Jinyoung Sohn, Youngmin Yoon, Sujeong Kim, Yunjae Kim, Hyemin Kim, Hongui Cha, Na‐Eun Lee, Hyunsuk Yang, Joo‐Yeon Chung, A‐Reum Jeong, Yun Yeon Kim, Sang Gyun Kim, Yeonhee Seo, Sehhoon Park, Hyun Ae Jung, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Hansoo Park, Kyoung Wan Yoon
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Advanced Science
Subjects:
anti‐tumor effects
CD8+ T cells
chemokine (CXC motif) ligand 13
immune checkpoint inhibitor
soluble ICAM‐1
Online Access:https://doi.org/10.1002/advs.202204378

Internet

https://doi.org/10.1002/advs.202204378

Similar Items